Considerations for the safe prescribing and use of COX-2-specific inhibitors

Simple item page
dc.contributor.authorBarraclough, D.
dc.contributor.authorBertouch, J.
dc.contributor.authorBrooks, P.
dc.contributor.authorBrown, M.
dc.contributor.authorCleland, L.
dc.contributor.authorClemens, L.
dc.contributor.authorCrowley, S.
dc.contributor.authorDay, R.
dc.contributor.authorDeJager, J.
dc.contributor.authorEdmonds, J.
dc.contributor.authorFletcher, P.
dc.contributor.authorFranks, G.
dc.contributor.authorHarris, D.
dc.contributor.authorHorowitz, J.
dc.contributor.authorJohnston, M.
dc.contributor.authorKerr, S.
dc.contributor.authorLittlejohn, G.
dc.contributor.authorMacDonald, G.
dc.contributor.authorMcColl, G.
dc.contributor.authorSambrook, P.
dc.contributor.authoret al.
dc.contributor.organisationThe Australian CSI Working Group
dc.date.issued2002
dc.description© 2002 The Medical Journal of Australia
dc.description.abstractThe majority of the "Australian COX-2-Specific Inhibitor (CSI) Prescribing Group" endorse the following points: CSIs are equivalent to non-steroidal anti-inflammatory drugs (NSAIDs) as anti-inflammatory agents. CSIs and NSAIDs modify symptoms but do not alter the course of musculoskeletal disease. CSIs do not eliminate the occurrence of ulcers or their serious complications, but are associated with considerably fewer peptic ulcers, slightly fewer upper GI symptoms and, according to published reports, fewer serious upper GI complications, notably bleeding, than CSIs and NSAIDs have similar effects on renal function and blood pressure. Whether any CSI poses a risk to cardiovascular safety remains subject to debate. Comorbidities and coprescribed drugs must be considered before initiating CSI (or NSAID) therapy. Patients prescribed CSIs (or NSAIDs) should be reviewed within the first few weeks of therapy to assess effectiveness, identify adverse effects and determine the need for ongoing therapy.
dc.description.statementofresponsibilityDavid R Barraclough, James V Bertouch, Peter Brooks, Mark A Brown, Leslie G Cleland, Laurie E Clemens, Steven J Crowley, Richard O Day, Julien P DeJager, John P Edmonds, Peter J Fletcher, Gary R Franks, David C Harris, John D Horowitz, Michael D Johnston, Stephen J Kerr, Geoff O Littlejohn, Graham J MacDonald, Geoff J McColl, Phillip N Sambrook, Sepehr Shakib, Murray W Verso and Neville D Yeomans
dc.identifier.citationMedical Journal of Australia, 2002; 176(7):328-331
dc.identifier.doi10.5694/j.1326-5377.2002.tb04434.x
dc.identifier.issn0025-729X
dc.identifier.issn1326-5377
dc.identifier.orcidHorowitz, J. [0000-0001-6883-0703]
dc.identifier.orcidShakib, S. [0000-0002-7199-5733]
dc.identifier.urihttp://hdl.handle.net/2440/9949
dc.language.isoen
dc.publisherAustralasian Med Publ Co Ltd
dc.source.urihttps://doi.org/10.5694/j.1326-5377.2002.tb04434.x
dc.subjectHumans
dc.subjectGastrointestinal Diseases
dc.subjectKidney Diseases
dc.subjectCardiovascular Diseases
dc.subjectSulfonamides
dc.subjectLactones
dc.subjectSulfones
dc.subjectPyrazoles
dc.subjectIsoenzymes
dc.subjectMembrane Proteins
dc.subjectCyclooxygenase Inhibitors
dc.subjectProstaglandin-Endoperoxide Synthases
dc.subjectCyclooxygenase 2
dc.subjectCyclooxygenase 2 Inhibitors
dc.subjectCelecoxib
dc.subjectPractice Patterns, Physicians'
dc.titleConsiderations for the safe prescribing and use of COX-2-specific inhibitors
dc.typeJournal article
pubs.publication-statusPublished

Files

Collections

Medicine publications